Immutep Ltd ADR (IMMP)

$0.38 -0.01 (-3.09%)
Market Cap 55.50M
Revenue (ttm) 6.69M
Net Income (ttm) -39.78M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -594.62%
Debt to Equity Ratio 0.01
Volume 585,300
Avg Vol 16,742,252
Day's Range N/A - N/A
Shares Out 147.37M
Stochastic %K 6%
Beta 2.21
Analysts Hold
Price Target $1.00

Company Profile

Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung...

Industry: Biotechnology
Sector: Healthcare
Phone: 61 2 8315 7003
Fax: 61 2 8569 1880
Address:
Australia Square, Level 32 264 George Street, Sydney, Australia
sunrisetiger
sunrisetiger Jun. 6 at 8:34 AM
$IMMP If a stock's closing bid price is below $1.00 for 30 consecutive business days. Has a deficiency notice been issued yet?
1 · Reply
Faisalfft
Faisalfft Jun. 5 at 7:23 PM
$IMMP Is there an analysis of the stock? Will it rise or continue to fall?
2 · Reply
hendo7179
hendo7179 Jun. 5 at 8:34 AM
$IMMP well, closer to 10c than $1.
1 · Reply
Hurtadogoalkeeper
Hurtadogoalkeeper Jun. 5 at 7:49 AM
$IMMP Yesterday news. https://www.immutep.com/immutep-to-present-positive-interim-phase-i-data-for-imp761-a-first-in-class-lag-3-agonist-antibody-at-eular-2026/
0 · Reply
focafoca99
focafoca99 Jun. 5 at 12:10 AM
$IMMP legal notice urges shareholders to contact SueWallSt for a securities class action over the TACTI-004 trial collapse.
0 · Reply
revuelto
revuelto Jun. 4 at 9:03 PM
$IMMP what made you call it that? Would genuinely love to hear your perspective…if you were just passing by and dropping a comment, take a little time to read up on the company and its programs first…then maybe pick up a few shares as a token of appreciation for what I believe is about to unfold in this space 😄
0 · Reply
sunrisetiger
sunrisetiger Jun. 4 at 8:06 PM
$IMMP junk
0 · Reply
Messerschmittbf109
Messerschmittbf109 Jun. 4 at 3:33 PM
$IMMP they have lost credibility….
0 · Reply
rispi
rispi Jun. 4 at 3:20 PM
$IMMP phase 1 announcement .....
0 · Reply
ToRni27
ToRni27 Jun. 4 at 3:08 PM
$IMMP its all fake…
0 · Reply
Latest News on IMMP
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

Sat, 06 Jun 2026 09:16:00 -0400 - 13 hours ago

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

IMMP Investors Have Opportunity to Lead Immutep Ltd. Securities Fraud Lawsuit

Fri, 05 Jun 2026 14:50:00 -0400 - 1 day ago

IMMP Investors Have Opportunity to Lead Immutep Ltd. Securities Fraud Lawsuit

Robbins LLP Reminds IMMP Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact the Firm for Information About Leading the Class Action Against Immutep Limited

Fri, 05 Jun 2026 13:57:00 -0400 - 1 day ago

Robbins LLP Reminds IMMP Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact the Firm for Information About Leading the Class Action Against Immutep Limited

ROSEN, LEADING INVESTOR COUNSEL, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

Fri, 05 Jun 2026 11:38:00 -0400 - 1 day ago

ROSEN, LEADING INVESTOR COUNSEL, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

Immutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMP

Fri, 05 Jun 2026 03:45:00 -0400 - 1 day ago

Immutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMP

IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm

Fri, 05 Jun 2026 02:40:00 -0400 - 1 day ago

IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

Thu, 04 Jun 2026 23:18:00 -0400 - 1 day ago

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

IMMP Shareholder Alert: Immutep Limited Securities Class Action Lawsuit - Investors Should Contact SueWallSt

Thu, 04 Jun 2026 17:33:00 -0400 - 2 days ago

IMMP Shareholder Alert: Immutep Limited Securities Class Action Lawsuit - Investors Should Contact SueWallSt

Bronstein, Gewirtz & Grossman LLC Urges Immutep Limited Investors to Act: Class Action Filed Alleging Investor Harm

Thu, 04 Jun 2026 12:00:00 -0400 - 2 days ago

Bronstein, Gewirtz & Grossman LLC Urges Immutep Limited Investors to Act: Class Action Filed Alleging Investor Harm

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines - IMMP

Thu, 04 Jun 2026 10:00:00 -0400 - 2 days ago

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines - IMMP

Immutep to present positive interim Phase I data for IMP761

2026-06-04T13:15:39.000Z - 2 days ago

Immutep to present positive interim Phase I data for IMP761

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Immutep Limited (IMMP)

Thu, 04 Jun 2026 09:14:00 -0400 - 2 days ago

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Immutep Limited (IMMP)

Immutep to Present Positive Interim Phase I Data for IMP761, a First-in-Class LAG-3 Agonist Antibody, at EULAR 2026

Thu, 04 Jun 2026 08:00:00 -0400 - 2 days ago

Immutep to Present Positive Interim Phase I Data for IMP761, a First-in-Class LAG-3 Agonist Antibody, at EULAR 2026

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

Wed, 03 Jun 2026 23:13:00 -0400 - 2 days ago

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

Bronstein, Gewirtz & Grossman LLC Urges Immutep Limited Investors to Act: Class Action Filed Alleging Investor Harm

Wed, 03 Jun 2026 12:00:00 -0400 - 3 days ago

Bronstein, Gewirtz & Grossman LLC Urges Immutep Limited Investors to Act: Class Action Filed Alleging Investor Harm

IMMP DEADLINE: Levi & Korsinsky Reminds Immutep Limited Investors of Upcoming Securities Class Action Deadline

Wed, 03 Jun 2026 09:00:00 -0400 - 3 days ago

IMMP DEADLINE: Levi & Korsinsky Reminds Immutep Limited Investors of Upcoming Securities Class Action Deadline

Immutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMP

Wed, 03 Jun 2026 03:02:00 -0400 - 3 days ago

Immutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMP

ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

Tue, 02 Jun 2026 23:13:00 -0400 - 3 days ago

ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

Tue, 02 Jun 2026 18:41:00 -0400 - 4 days ago

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines – IMMP

Tue, 02 Jun 2026 16:32:00 -0400 - 4 days ago

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines – IMMP

IMMP Shareholder Alert: Immutep Limited Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky

Tue, 02 Jun 2026 16:00:00 -0400 - 4 days ago

IMMP Shareholder Alert: Immutep Limited Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky

IMMP INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Immutep (IMMP) Investors of Securities Class Action Deadline on July 6, 2026

Tue, 02 Jun 2026 12:49:00 -0400 - 4 days ago

IMMP INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Immutep (IMMP) Investors of Securities Class Action Deadline on July 6, 2026

IMMUTEP LIMITED INVESTORS WITH LOSSES HAVE UNTIL JULY 6, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Deadline

Tue, 02 Jun 2026 09:33:00 -0400 - 4 days ago

IMMUTEP LIMITED INVESTORS WITH LOSSES HAVE UNTIL JULY 6, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Deadline

IMMP Shareholder Alert: Immutep Limited Securities Class Action Lawsuit - Investors With Losses May Contact The Gross Law Firm

Tue, 02 Jun 2026 09:00:00 -0400 - 4 days ago

IMMP Shareholder Alert: Immutep Limited Securities Class Action Lawsuit - Investors With Losses May Contact The Gross Law Firm

IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm

Tue, 02 Jun 2026 08:20:00 -0400 - 4 days ago

IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm

ROSEN, A LONGSTANDING FIRM, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

Mon, 01 Jun 2026 23:13:00 -0400 - 4 days ago

ROSEN, A LONGSTANDING FIRM, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 6, 2026 in Immutep Limited Lawsuit - IMMP

Mon, 01 Jun 2026 14:33:00 -0400 - 5 days ago

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 6, 2026 in Immutep Limited Lawsuit - IMMP

Bronstein, Gewirtz & Grossman LLC Urges Immutep Limited Investors to Act: Class Action Filed Alleging Investor Harm

Mon, 01 Jun 2026 12:00:00 -0400 - 5 days ago

Bronstein, Gewirtz & Grossman LLC Urges Immutep Limited Investors to Act: Class Action Filed Alleging Investor Harm

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Immutep (IMMP) Investors of Securities Class Action Deadline on July 6, 2026

Mon, 01 Jun 2026 11:52:00 -0400 - 5 days ago

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Immutep (IMMP) Investors of Securities Class Action Deadline on July 6, 2026

IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm

Mon, 01 Jun 2026 03:58:00 -0400 - 5 days ago

IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm

Bronstein, Gewirtz & Grossman LLC Urges Immutep Limited Investors to Act: Class Action Filed Alleging Investor Harm

Sun, 31 May 2026 12:00:00 -0400 - 6 days ago

Bronstein, Gewirtz & Grossman LLC Urges Immutep Limited Investors to Act: Class Action Filed Alleging Investor Harm

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

Sun, 31 May 2026 10:42:00 -0400 - 6 days ago

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

IMMP DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Immutep (IMMP) Investors of Securities Class Action Deadline on July 6, 2026

Sun, 31 May 2026 09:04:00 -0400 - 6 days ago

IMMP DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Immutep (IMMP) Investors of Securities Class Action Deadline on July 6, 2026

IMMP CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Immutep (IMMP) Investors of Securities Class Action Deadline on July 6, 2026

Sat, 30 May 2026 08:36:00 -0400 - 7 days ago

IMMP CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Immutep (IMMP) Investors of Securities Class Action Deadline on July 6, 2026

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

Sat, 30 May 2026 07:13:00 -0400 - 7 days ago

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

IMMP Investors Have Opportunity to Lead Immutep Ltd. Securities Fraud Lawsuit

Fri, 29 May 2026 19:13:00 -0400 - 8 days ago

IMMP Investors Have Opportunity to Lead Immutep Ltd. Securities Fraud Lawsuit

Bronstein, Gewirtz & Grossman LLC Urges Immutep Limited Investors to Act: Class Action Filed Alleging Investor Harm

Fri, 29 May 2026 12:00:00 -0400 - 8 days ago

Bronstein, Gewirtz & Grossman LLC Urges Immutep Limited Investors to Act: Class Action Filed Alleging Investor Harm

IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm

Fri, 29 May 2026 10:34:00 -0400 - 8 days ago

IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 6, 2026 in Immutep Limited Lawsuit - IMMP

Fri, 29 May 2026 09:00:00 -0400 - 8 days ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 6, 2026 in Immutep Limited Lawsuit - IMMP

IMMP UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Immutep (IMMP) Investors of Securities Class Action Deadline on July 6, 2026

Fri, 29 May 2026 08:19:00 -0400 - 8 days ago

IMMP UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Immutep (IMMP) Investors of Securities Class Action Deadline on July 6, 2026

ROSEN, A LEADING LAW FIRM, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

Thu, 28 May 2026 14:45:00 -0400 - 9 days ago

ROSEN, A LEADING LAW FIRM, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines - IMMP

Thu, 28 May 2026 10:00:00 -0400 - 9 days ago

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines - IMMP

IMMUTEP LIMITED INVESTORS WITH LOSSES HAVE UNTIL JULY 6, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Deadline

Thu, 28 May 2026 09:16:00 -0400 - 9 days ago

IMMUTEP LIMITED INVESTORS WITH LOSSES HAVE UNTIL JULY 6, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Deadline

SueWallSt Reminds Immutep Limited Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of July 6, 2026 - IMMP

Thu, 28 May 2026 09:00:00 -0400 - 9 days ago

SueWallSt Reminds Immutep Limited Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of July 6, 2026 - IMMP

ROSEN, A RANKED AND LEADING FIRM, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

Wed, 27 May 2026 22:28:00 -0400 - 10 days ago

ROSEN, A RANKED AND LEADING FIRM, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

IMMP INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Immutep (IMMP) Investors of Securities Class Action Deadline on July 6, 2026

Wed, 27 May 2026 12:20:00 -0400 - 10 days ago

IMMP INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Immutep (IMMP) Investors of Securities Class Action Deadline on July 6, 2026

Bronstein, Gewirtz & Grossman LLC Urges Immutep Limited Investors to Act: Class Action Filed Alleging Investor Harm

Wed, 27 May 2026 12:00:00 -0400 - 10 days ago

Bronstein, Gewirtz & Grossman LLC Urges Immutep Limited Investors to Act: Class Action Filed Alleging Investor Harm

IMMP Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Immutep Limited Securities Lawsuit - Contact Levi & Korsinsky

Wed, 27 May 2026 09:00:00 -0400 - 10 days ago

IMMP Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Immutep Limited Securities Lawsuit - Contact Levi & Korsinsky

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Immutep Limited (IMMP)

Wed, 27 May 2026 08:36:00 -0400 - 10 days ago

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Immutep Limited (IMMP)

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

Tue, 26 May 2026 22:06:00 -0400 - 11 days ago

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

IMMUTEP LIMITED (IMMP) INVESTOR ALERT Investors With Large Losses in Immutep Limited Should Contact Bernstein Liebhard LLP To Discuss Their Rights

May 7, 2026, 9:03 AM EDT - 4 weeks ago

IMMUTEP LIMITED (IMMP) INVESTOR ALERT Investors With Large Losses in Immutep Limited Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Immutep receives noncompliance notification from Nasdaq

2026-04-30T14:06:28.000Z - 5 weeks ago

Immutep receives noncompliance notification from Nasdaq

3 Penny Stocks to Watch Now, 4/16/26

2026-04-16T18:52:15.000Z - 7 weeks ago

3 Penny Stocks to Watch Now, 4/16/26

BIRD

Why Is Immutep Stock (IMMP) Up Today?

2026-04-15T13:01:30.000Z - 7 weeks ago

Why Is Immutep Stock (IMMP) Up Today?

Immutep granted Orphan Drug Designation for eftilagimod alfa

2026-04-15T12:23:31.000Z - 7 weeks ago

Immutep granted Orphan Drug Designation for eftilagimod alfa

Immutep Receives FDA Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue Sarcoma

Apr 15, 2026, 8:00 AM EDT - 7 weeks ago

Immutep Receives FDA Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue Sarcoma

Immutep sees progress from Phase I study of LAG-3 agonist for autoimmune disease

2026-03-19T12:28:18.000Z - 2 months ago

Immutep sees progress from Phase I study of LAG-3 agonist for autoimmune disease

Immutep Limited Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Mar 16, 2026, 8:03 AM EDT - 2 months ago

Immutep Limited Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Why Did Investors Lose Faith In Immutep Stock (IMMP) Today?

2026-03-14T00:11:00.000Z - 3 months ago

Why Did Investors Lose Faith In Immutep Stock (IMMP) Today?

Immutep downgraded to Hold from Buy at Maxim

2026-03-13T16:52:01.000Z - 3 months ago

Immutep downgraded to Hold from Buy at Maxim

Immutep says IDMC recommends discontinuation for TACTI-004 Phase III study

2026-03-13T12:12:46.000Z - 3 months ago

Immutep says IDMC recommends discontinuation for TACTI-004 Phase III study

Immutep downgraded to Neutral from Outperform at Baird

2026-03-13T09:35:41.000Z - 3 months ago

Immutep downgraded to Neutral from Outperform at Baird

Immutep downgraded to Market Perform from Outperform at Citizens

2026-03-13T08:45:13.000Z - 3 months ago

Immutep downgraded to Market Perform from Outperform at Citizens

Immutep Quarterly report: H1 2026

Feb 24, 2026, 6:00 PM EST - 3 months ago

Immutep Quarterly report: H1 2026

Immutep initiated with an Outperform at Citizens

2026-02-17T09:55:08.000Z - 3 months ago

Immutep initiated with an Outperform at Citizens

Immutep achieves 50% enrollment in global TACTI-004 Phase III trial

2026-02-06T13:06:35.000Z - 4 months ago

Immutep achieves 50% enrollment in global TACTI-004 Phase III trial

Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLC

Feb 6, 2026, 8:00 AM EST - 4 months ago

Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLC

Immutep reports Q2 cash receipts from customers A$4,000

2026-01-29T13:21:20.000Z - 4 months ago

Immutep reports Q2 cash receipts from customers A$4,000

Immutep Quarterly Activities Report Q2 FY26

Jan 29, 2026, 8:00 AM EST - 4 months ago

Immutep Quarterly Activities Report Q2 FY26

Immutep Earnings release: Q2 2026

Jan 28, 2026, 6:00 PM EST - 4 months ago

Immutep Earnings release: Q2 2026

Immutep announces update on IMP761 from Phase I study

2025-12-22T13:15:55.000Z - 5 months ago

Immutep announces update on IMP761 from Phase I study

Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I Study

Dec 22, 2025, 8:00 AM EST - 5 months ago

Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I Study

India's Dr Reddy's signs licensing pact to sell Immutep's cancer drug

Dec 8, 2025, 2:34 AM EST - 6 months ago

India's Dr Reddy's signs licensing pact to sell Immutep's cancer drug

Immutep Transcript: AGM 2025

Nov 26, 2025, 7:30 PM EST - 6 months ago

Immutep Transcript: AGM 2025

Immutep Slides: FY 2025

Nov 26, 2025, 7:30 PM EST - 6 months ago

Immutep Slides: FY 2025

Immutep Transcript: Bell Potter Healthcare Conference 2025

Nov 19, 2025, 5:00 PM EST - 7 months ago

Immutep Transcript: Bell Potter Healthcare Conference 2025

Immutep Earnings release: Q1 2026

Oct 28, 2025, 6:00 PM EDT - 7 months ago

Immutep Earnings release: Q1 2026

Primary Endpoint Met in EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma and Data Presented at ESMO Congress 2025

Oct 20, 2025, 8:01 AM EDT - 8 months ago

Primary Endpoint Met in EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma and Data Presented at ESMO Congress 2025

Immutep Annual report: H2 2025

Oct 9, 2025, 10:00 AM EDT - 8 months ago

Immutep Annual report: H2 2025

Immutep Annual report: H2 2025

Oct 9, 2025, 10:00 AM EDT - 8 months ago

Immutep Annual report: H2 2025

Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025

Sep 8, 2025, 8:00 AM EDT - 9 months ago

Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025

Immutep Quarterly Activities Report Q4 FY25

Jul 30, 2025, 8:00 AM EDT - 11 months ago

Immutep Quarterly Activities Report Q4 FY25

Immutep Earnings release: Q4 2025

Jul 29, 2025, 6:00 PM EDT - 11 months ago

Immutep Earnings release: Q4 2025

Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer

Jul 29, 2025, 8:00 AM EDT - 11 months ago

Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer

Immutep Transcript: Jefferies Global Healthcare Conference 2025

Jun 5, 2025, 11:40 AM EDT - 1 year ago

Immutep Transcript: Jefferies Global Healthcare Conference 2025

Immutep Slides: Corporate Presentation

Jun 1, 2025, 6:00 PM EDT - 1 year ago

Immutep Slides: Corporate Presentation

Immutep's Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma

May 27, 2025, 8:00 AM EDT - 1 year ago

Immutep's Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma

Immutep Earnings release: Q3 2025

Apr 28, 2025, 6:00 PM EDT - 1 year ago

Immutep Earnings release: Q3 2025

Immutep to Participate in Upcoming Investor Conferences

Apr 2, 2025, 8:00 AM EDT - 1 year ago

Immutep to Participate in Upcoming Investor Conferences

Immutep Quarterly report: H1 2025

Feb 25, 2025, 6:00 PM EST - 1 year ago

Immutep Quarterly report: H1 2025

Immutep Quarterly Activities Report Q2 FY25

Jan 31, 2025, 8:00 AM EST - 1 year ago

Immutep Quarterly Activities Report Q2 FY25

Immutep Earnings release: Q2 2025

Jan 30, 2025, 6:00 PM EST - 1 year ago

Immutep Earnings release: Q2 2025

Immutep Transcript: Baird's Biotech Discovery Series

Dec 19, 2024, 10:15 AM EST - 1 year ago

Immutep Transcript: Baird's Biotech Discovery Series

Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761

Dec 17, 2024, 8:00 AM EST - 1 year ago

Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761

Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024

Dec 12, 2024, 8:15 AM EST - 1 year ago

Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024

Immutep Transcript: AGM 2024

Nov 21, 2024, 6:30 PM EST - 1 year ago

Immutep Transcript: AGM 2024

Immutep Slides: FY 2024

Nov 21, 2024, 6:30 PM EST - 1 year ago

Immutep Slides: FY 2024

Immutep's Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer

Nov 14, 2024, 8:15 AM EST - 1 year ago

Immutep's Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer

Immutep Quarterly Activities Report Q1 FY25

Oct 29, 2024, 8:00 AM EDT - 1 year ago

Immutep Quarterly Activities Report Q1 FY25

Immutep Annual report: H2 2024

Oct 22, 2024, 3:30 AM EDT - 1 year ago

Immutep Annual report: H2 2024

Immutep Annual report: H2 2024

Oct 22, 2024, 3:30 AM EDT - 1 year ago

Immutep Annual report: H2 2024

Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit

Oct 10, 2024, 8:00 AM EDT - 1 year ago

Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit

Immutep's Efti in Combination with MSD's KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer

Sep 16, 2024, 8:00 AM EDT - 1 year ago

Immutep's Efti in Combination with MSD's KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer

Immutep Slides: Corporate Presentation

Aug 21, 2024, 2:00 AM EDT - 1 year ago

Immutep Slides: Corporate Presentation

Immutep Transcript: Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024

Aug 14, 2024, 8:30 AM EDT - 1 year ago

Immutep Transcript: Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024

Immutep Quarterly Activities Report Q4 FY24

Jul 31, 2024, 8:00 AM EDT - 2 years ago

Immutep Quarterly Activities Report Q4 FY24

Immutep Slides: Study Update Presentation

Jul 11, 2024, 7:00 PM EDT - 2 years ago

Immutep Slides: Study Update Presentation

Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression

Jul 11, 2024, 6:40 PM EDT - 2 years ago

Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression

Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical Results

Jul 3, 2024, 8:00 AM EDT - 2 years ago

Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical Results

Immutep Slides: Study Result Presentation

Jun 26, 2024, 7:00 PM EDT - 2 years ago

Immutep Slides: Study Result Presentation

Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer

Jun 25, 2024, 8:00 AM EDT - 2 years ago

Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer

Immutep successfully completes institutional placement and institutional component of entitlement offer

Jun 5, 2024, 6:00 AM EDT - 2 years ago

Immutep successfully completes institutional placement and institutional component of entitlement offer

Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial

Jun 2, 2024, 8:38 PM EDT - 2 years ago

Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial

Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024

May 15, 2024, 8:00 AM EDT - 2 years ago

Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024

Positive Initial Clinical Data Reported from Immutep's Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma

May 2, 2024, 8:00 AM EDT - 2 years ago

Positive Initial Clinical Data Reported from Immutep's Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma

Immutep Quarterly Activities Report Q3 FY24

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Immutep Quarterly Activities Report Q3 FY24

Immutep Earnings release: Q3 2024

Apr 28, 2024, 8:00 PM EDT - 2 years ago

Immutep Earnings release: Q3 2024

Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B

Apr 24, 2024, 8:00 AM EDT - 2 years ago

Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B

Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761

Apr 18, 2024, 8:00 AM EDT - 2 years ago

Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761

Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Apr 17, 2024, 8:00 AM EDT - 2 years ago

Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Immutep Announces First Clinical Data from 90mg Dosing of Efti

Mar 5, 2024, 8:00 AM EST - 2 years ago

Immutep Announces First Clinical Data from 90mg Dosing of Efti

Immutep Quarterly Activities Report Q2 FY24

Jan 30, 2024, 8:00 AM EST - 2 years ago

Immutep Quarterly Activities Report Q2 FY24

Immutep Earnings release: Q2 2024

Jan 30, 2024, 2:30 AM EST - 2 years ago

Immutep Earnings release: Q2 2024

First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer

Jan 4, 2024, 8:00 AM EST - 2 years ago

First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer

Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Dec 21, 2023, 8:00 AM EST - 2 years ago

Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Immutep Receives A$2.6 million R&D Tax Incentive from French Government

Dec 7, 2023, 8:00 AM EST - 2 years ago

Immutep Receives A$2.6 million R&D Tax Incentive from French Government

Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial

Nov 22, 2023, 8:00 AM EST - 2 years ago

Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial

Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA® in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

Nov 9, 2023, 8:00 AM EST - 2 years ago

Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA® in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast Cancer

Nov 6, 2023, 8:00 AM EST - 2 years ago

Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast Cancer

sunrisetiger
sunrisetiger Jun. 6 at 8:34 AM
$IMMP If a stock's closing bid price is below $1.00 for 30 consecutive business days. Has a deficiency notice been issued yet?
1 · Reply
Faisalfft
Faisalfft Jun. 5 at 7:23 PM
$IMMP Is there an analysis of the stock? Will it rise or continue to fall?
2 · Reply
hendo7179
hendo7179 Jun. 5 at 8:34 AM
$IMMP well, closer to 10c than $1.
1 · Reply
Hurtadogoalkeeper
Hurtadogoalkeeper Jun. 5 at 7:49 AM
$IMMP Yesterday news. https://www.immutep.com/immutep-to-present-positive-interim-phase-i-data-for-imp761-a-first-in-class-lag-3-agonist-antibody-at-eular-2026/
0 · Reply
focafoca99
focafoca99 Jun. 5 at 12:10 AM
$IMMP legal notice urges shareholders to contact SueWallSt for a securities class action over the TACTI-004 trial collapse.
0 · Reply
revuelto
revuelto Jun. 4 at 9:03 PM
$IMMP what made you call it that? Would genuinely love to hear your perspective…if you were just passing by and dropping a comment, take a little time to read up on the company and its programs first…then maybe pick up a few shares as a token of appreciation for what I believe is about to unfold in this space 😄
0 · Reply
sunrisetiger
sunrisetiger Jun. 4 at 8:06 PM
$IMMP junk
0 · Reply
Messerschmittbf109
Messerschmittbf109 Jun. 4 at 3:33 PM
$IMMP they have lost credibility….
0 · Reply
rispi
rispi Jun. 4 at 3:20 PM
$IMMP phase 1 announcement .....
0 · Reply
ToRni27
ToRni27 Jun. 4 at 3:08 PM
$IMMP its all fake…
0 · Reply
ckruel
ckruel Jun. 4 at 1:29 PM
$IMMP https://finance.yahoo.com/sectors/healthcare/articles/immutep-present-positive-interim-phase-120000283.html
0 · Reply
Alexnova
Alexnova Jun. 4 at 10:30 AM
$IMMP https://www.marketindex.com.au/asx/imm/announcements/immutep-presents-positive-imp761-phase-i-data-at-eular-2026-2A1675473 Initial clinical findings showed significant and clinically relevant pharmacodynamic activity, including reduction of local inflammatory responses and attenuated T-cell activity compared to placebo across cohorts ranging from 0.9 mg/kg to 7 mg/kg, with 7 mg/kg being statistically significantly better in terms of skin blood perfusion compared to placebo (p = 0.029). IMP761 was safe and very well tolerated at all dose levels tested and the study successfully reached its primary endpoint for the single ascending dose part of the study. The pharmacokinetics of single ascending doses of IMP761 support once per 4-week dosing. The results highlight the potential of IMP761 to treat multiple autoimmune diseases driven by T- cell mediated inflammation and support further evaluation in a Phase II setting
0 · Reply
Bruyne
Bruyne Jun. 4 at 7:27 AM
$IMMP news out for 761!
1 · Reply
DNAenvy
DNAenvy Jun. 4 at 5:52 AM
$IMMP Just to put in context, I'm not bullish or bearish on this stock. I've clearly got no idea. I thought buying at 0.24c (ASX) was a great move for a while. I hold 300,000 shares. Major brokerage firms had the stock undervalued and a strong buy for years before I got involved. I'm resigned to accept whatever happens next and just put it down to a learning experience. You can feel like a genius one day and an idiot the next.
0 · Reply
rispi
rispi Jun. 3 at 7:32 PM
$IMMP ohhh windy clown
0 · Reply
DNAenvy
DNAenvy Jun. 3 at 4:13 PM
$IMMP I'm thinking an official price sensitive announcement should be imminent. I'm hoping the entity selling these large blocks of shares is for tax purposes. In Australia the financial year ends June 30.
1 · Reply
DNAenvy
DNAenvy Jun. 3 at 8:35 AM
$IMMP another day another big trade after the ASX closed.
0 · Reply
bkfViking123
bkfViking123 Jun. 3 at 1:14 AM
$IMMP and out lic. also
1 · Reply
bkfViking123
bkfViking123 Jun. 3 at 1:10 AM
$IMMP $IMMP efti (which turns the immune system on to fight cancer), IMP761 is a first-in-class LAG-3 agonist designed to turn the immune system off to treat autoimmune conditions like rheumatoid arthritis, multiple sclerosis, and Type 1 diabetes. data> June 4, 2026, at 1:30 PM UK
0 · Reply
DNAenvy
DNAenvy Jun. 2 at 2:03 PM
$IMMP this is what was happening today on the ASX
0 · Reply
DNAenvy
DNAenvy Jun. 2 at 1:58 PM
$IMMP there was a large trade of 25 million+ shares on the ASX approx half an hour after closing today.
0 · Reply
IFeelLike
IFeelLike Jun. 1 at 6:29 PM
$IMMP remember June 4th... 90 billion USD markets to be served? -Rheumatoid Arthritis (RA) -Multiple Sclerosis (MS) -Type 1 Diabetes -Inflammatory Bowel Disease (IBD) to name a few.... After root cause analysis tacti004, hopefully trial for new group.
2 · Reply